Access Update- #23

It’s time to add another position to the portfolio.

Buy ViroPharma(Nadsaq: VPHM) up to $12.50 .

ViroPharma is the ultimate contrarian biotech play. Bad news is already priced into the stock as Wall Street believes a generic competitor to the company’s only marketed drug, Vancocin, is just around the corner.

However, it’s not quite that simple. There is a dispute as to whether the FDA’s requirements to prove bioequivalence in generic Vancocin are sufficient to protect the public. If generic competition is delayed, as we believe it will be, the ceiling on the shares should be lifted.

Additionally, ViroPharma has a prospective standard of care therapy for CMV and is in the process of acquiring a company that will give it a phase III orphan drug candidate in a rare but potentially lucrative disease. These two catalysts should move the stock price significantly in the future.

You can view the full report by clicking here or by visiting our website .

The conference call is tentatively scheduled for the first week in August. We will provide more information once the details have been confirmed.

Another Recommendation in August

We are making good progress on our next recommendation. The company we are looking at has an exciting drug in phase III trials that fights a difficult form of cancer. If the drug is approved, the company will have the market to itself.

I’m speaking with the CEO this afternoon, and will update you as our progress continues.

Have a great weekend.

Marc Lichtenfeld
Director of Research
Access Research Group

Stock
Symbol
Current Price
Comments

ViroPharma

VPHM

New

Buy up to $12.50

Cytori Therapeutics

CYTX

$7.09

Buy up to $8

Electro-Optical Sciences

MELA

$6.47

Buy up to $5.75